Google Halts UK YouTube TV Measurement Service After Legal Action 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
IRVINE, Calif., May 23, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX). Investors who purchased or otherwise acquired shares between March 30, 2017 and May 11, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the July 11, 2017 lead plaintiff motion deadline.
If you purchased Akari shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose that: Chief Executive Officer Dr. Gur Roshwalb and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; that Akari lacked adequate checks and protections to prevent such behavior; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On May 11, 2017, Akari announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and subsequently withdrawn in April 26, 2017 by Edison Investment Research Ltd. When this information was released, Akari shares fell in value materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
